



2nd Quarter & 1st Half 2015 Review

July 30 2015

Safe Harbor Statement under the U.S. Private Securities Litigation Reform Act of 1995:

This release contains forward-looking statements, which are based on management's current beliefs and expectations and involve a number of known and unknown risks and uncertainties that could cause our future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to: our ability to develop and commercialize additional pharmaceutical products; competition for our specialty products, especially Copaxone® (including competition from orally-administered alternatives, as well as from generic equivalents such as the recently launched Sandoz product) and our ability to continue to migrate users to our 40 mg/mL version and maintain patients on that version; our ability to identify and successfully bid for suitable acquisition targets or licensing opportunities (such as our pending acquisition of Allergan's generics business), or to consummate and integrate acquisitions; the possibility of material fines, penalties and other sanctions and other adverse consequences arising out of our ongoing FCPA investigations and related matters; our ability to achieve expected results from the research and development efforts invested in our pipeline of specialty and other products; our ability to reduce operating expenses to the extent and during the timeframe intended by our cost reduction program; the extent to which any manufacturing or quality control problems damage our reputation for quality production and require costly remediation; increased government scrutiny in both the U.S. and Europe of our patent settlement agreements; our exposure to currency fluctuations and restrictions as well as credit risks; the effectiveness of our patents, confidentiality agreements and other measures to protect the intellectual property rights of our specialty medicines; the effects of reforms in healthcare regulation and pharmaceutical pricing, reimbursement and coverage; governmental investigations into sales and marketing practices, particularly for our specialty pharmaceutical products; adverse effects of political or economic instability, major hostilities or acts of terrorism on our significant worldwide operations; interruptions in our supply chain or problems with internal or third-party information technology systems that adversely affect our complex manufacturing processes; significant disruptions of our information technology systems or breaches of our data security; competition for our generic products, both from other pharmaceutical companies and as a result of increased governmental pricing pressures; competition for our specialty pharmaceutical businesses from companies with greater resources and capabilities; the impact of continuing consolidation of our distributors and customers; decreased opportunities to obtain U.S. market exclusivity for significant new generic products; potential liability in the U.S., Europe and other markets for sales of generic products prior to a final resolution of outstanding patent litigation; our potential exposure to product liability claims that are not covered by insurance; any failure to recruit or retain key personnel, or to attract additional executive and managerial talent; any failures to comply with complex Medicare and Medicaid reporting and payment obligations; significant impairment charges relating to intangible assets, goodwill and property, plant and equipment; the effects of increased leverage and our resulting reliance on access to the capital markets; potentially significant increases in tax liabilities; the effect on our overall effective tax rate of the termination or expiration of governmental programs or tax benefits, or of a change in our business; variations in patent laws that may adversely affect our ability to manufacture our products in the most efficient manner; environmental risks; and other factors that are discussed in our Annual Report on Form 20-F for the year ended December 31, 2014 and in our other filings with the U.S. Securities and Exchange Commission (the "SEC").

Forward-looking statements speak only as of the date on which they are made and we assume no obligation to update or revise any forward-looking statements or other information contained in this report, whether as a result of new information, future events or otherwise. You are advised, however, to consult any additional disclosures we make in our reports to the SEC on Form 6-K. Also note that we provide a cautionary discussion of risks and uncertainties under "Risk Factors" in our Annual Report on Form 20-F for the year ended December 31, 2014. These are factors that we believe could cause our actual results to differ materially from expected results. Other factors besides those listed could also adversely affect us. This discussion is provided as permitted by the Private Securities Litigation Reform Act of 1995.

Erez Vigodman

President & CEO

Eyal Desheh

EVP, Chief Financial Officer

Second Quarter 2015 Results

Q2 2015 – An Outstanding Quarter for Teva

	Q2 2015	Q2 2014*	Change
Revenues \$m	4,966	5,045	(2%)
Operating Income \$m	1,610 (32.4%)	1,387 (27.5%)	+16%
Net Income \$m	1,230 (24.8%)	1,069 (21.2%)	+15%
EPS \$	1.43	1.25	+14%
Cash flow from Operations \$m	1,480	1,053	+41%
Free Cash Flow \$m	1,336	882	+51%

* Includes adjustments for the removal of equity compensation


Foreign Exchange Impact

	Q2 2015	Q2 2014	Change (\$m)	Fx Effect* (\$m)	Real Change
Revenues \$m	4,966	5,045	(79)	(341)	+262
Operating income \$m	1,610	1,387	223	(4)	+227

*Includes profits from certain hedging transactions

Cash Flow Trends


\$ million



* Commencing Q4 2014, the data presented has been conformed to reflect the revised definition of free cash flow before dividend, for all periods.


Quarterly Revenue Breakdown by Market

\$ million




Quarterly Revenue Breakdown by Segment

\$ million



Quarterly Revenues

\$ million




All data, except Fx, are net of the impact of foreign exchange fluctuations.

*includes impact of U.S. OTC plants divestment

Copaxone® Revenues Evolution


US demand is stable despite generic launch



* Market share data, including historic data, is based on IMS June 2015 data.

Revenues and Profitability Evolution

Focus and efficiency gains are reflected in improved profitability for the Company




\$ million

Net Revenue Operating Margin

Continuous Improvement of Our Generics Business


Generics Segment Gross Profit and Profit* Margin Evolution



* Segment profit consists of gross profit, less S&M and R&D expenses related to the segment. Segment profit does not include G&A expenses, amortization and certain other items.

Quarterly Operating Income

\$ million



Operating Income increased 16% year-over-year

1st Half 2015 – Strong Results


	H1 2015	H1 2014	Change
Revenues \$m	9,948	10,046	(1%)
Operating Income \$m	3,143	2,768	+14%
Net Income \$m	2,393	2,120	+13%
EPS \$	2.79	2.48	+13%
Cash flow from Operations \$m	2,834	1,951	+45%
Free Cash Flow \$m	2,549	1,555	+64%

2015 Business Outlook: Increased Again as a Result of Improvements in Core Business Performance and Operating Efficiency

	December 11, 2014	July 30, 2015
Net Revenues (\$b)	19.0-19.4	19.0 - 19.4
Gross Profit (%)	59.5%-61.5%	60.5% - 62.5%
R&D (\$b)	1.3-1.4	1.3 - 1.4
S&M (\$b)	3.3-3.5	3.3 - 3.5
G&A (\$b)	1.1-1.2	1.1
Operating Income* (\$b)	5.7-5.9	5.8 - 6.0
Finance Expenses (\$m)	250-290	220 - 260
Tax (%)	19%-21%	20% - 22%
Number of Shares (M)	850-860	860 - 865
EPS (\$)	5.00-5.30	5.15 - 5.40
Cash Flow from Operations (\$b)	4.3-4.7	4.4 – 4.8

Quarterly Dividends

Teva's Dividend Payments



Total dividends represent payment of the dividend declared for the quarter. Current quarter data is an estimate.

Q&A

Additional Information



H1 2015 Non-GAAP Income Data

\$ million Except EPS	H1-15	H1 2015 Margins	H1-14	H1 2014 Margins	Change
Revenues	9,948		10,046		(1%)
COGS	3,766	37.9%	4,129	41.1%	(9%)
Gross Profit	6,182	62.1%	5,917	58.9%	+4%
R&D	685	6.9%	691	6.9%	(1%)
S&M	1,754	17.6%	1,874	18.7%	(6%)
G&A	600	6.0%	584	5.8%	+3%
Operating Income	3,143	31.6%	2,768	27.6%	+14%
Finance exp.	90		160		(44%)
Tax	657		487		+35%
Net Income	2,395	24.1%	2,120	21.1%	+13%
# of Shares (diluted, millions)	859		855		
EPS (\$)	2.79		2.48		+13%

H1 2015 GAAP Income Data

\$ million except EPS	H1-15	H1 2015 Margins	H1-14	H1 2014 Margins	Change
Revenues	9,948		10,046		(1%)
COGS	4,210	42.3%	4,688	46.7%	(10%)
Gross Profit	5,738	57.7%	5,358	53.3%	+7%
R&D	718	7.2%	697	6.9%	+3%
S&M	1,782	17.9%	1,905	19.0%	(6%)
G&A	632	6.4%	604	6.0%	+5%
Legal settlements and loss contingencies	611	6.1%	55	0.5%	+1011%
Impairments, restructuring and others	584	5.9%	200	2.0%	+192%
Operating Income	1,411	14.2%	1,897	18.9%	(26%)
Finance exp.	233	2.3%	159	1.6%	+47%
Tax	192	1.9%	245	2.4%	(22%)
Net Income	983	9.9%	1,485	14.8%	(34%)
# of Shares (diluted, millions)	859		855		
EPS (\$)	1.15		1.75		(34%)

Q2 2015 Non-GAAP Income Data

\$ million Except EPS	Q2 2015	Q2 15 margins	Q2 2014	Q2 14 margins	Change
Revenues	4,966		5,045		(2%)
COGS	1,846	37.2%	2,116	41.9%	(13%)
Gross Profit	3,120	62.8%	2,929	58.1%	+7%
R&D	357	7.2%	340	6.7%	+5%
S&M	846	17.0%	911	18.1%	(7%)
G&A	307	6.2%	291	5.8%	+5%
Operating Income	1,610	32.4%	1,387	27.5%	+16%
Finance exp.	41		76		(46%)
Tax	345		245		+41%
Net Income	1,230	24.8%	1,069	21.2%	+15%
# of Shares (diluted, millions)	859		857		
EPS (\$)	1.43		1.25		+14%

Q2 2015 GAAP Income Data

\$ million Except EPS	Q2-15	Q2 2015 Margins	Q2-14	Q2 2014 Margins	Change
Revenues	4,966		5,045		(2%)
COGS	2,064	41.6%	2,384	47.3%	(13%)
Gross Profit	2,902	58.4%	2,661	52.7%	+9%
R&D	386	7.8%	344	6.8%	+12%
S&M	860	17.3%	921	18.3%	(7%)
G&A	325	6.5%	302	6.0%	+8%
Legal settlements and loss contingencies	384	7.7%	26	0.5%	+1377%
Impairments, restructuring and others	285	5.7%	143	2.8%	+99%
Operating Income	662	13.3%	925	18.3%	(28%)
Finance exp.	41	0.8%	78	1.5%	(47%)
Tax	88	1.1%	102	2.0%	(14%)
Net Income	539	10.9%	745	14.8%	(28%)
# of Shares (diluted, millions)	859		857		
EPS (\$)	0.63		0.87		(28%)